Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2022 Publisher: Bausch Health Ireland Limited, 3013 Lake Drive, Citywest Business Campus, Dublin 24, D24PPT3, Ireland
Tetrabenazine 25 mg Tablets.
Xenazine 25.
| Pharmaceutical Form |
|---|
|
Tablet. Yellowish-buff, circular, bevel-edged tablets with ‘CL25’ on one face and a single scoreline on the other. The tablet can be divided into equal halves. |
Each tablet contains 25 mg tetrabenazine.
Excipient: Each tablet also contains 64 mg of lactose monohydrate.
For a full list of excipients, see Section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Tetrabenazine |
Tetrabenazine is a synthetic derivative of benzylquinolizine that causes depletion of dopamine and other monoamines in the central nervous system. The precise mechanism by which tetrabenazine exerts its effects is unknown, but is believed to be related to its effect as a reversible depletor of monoamines (such as dopamine, serotonin, norepinephrine, and histamine) from nerve terminals. Neurotransmitter depletion by a single dose of tetrabenazine is reversible and lasts only a few hours. |
| List of Excipients |
|---|
|
Maize starch |
White HDPE bottle with a white HDPE cap. Pack size of 112 tablets.
Bausch Health Ireland Limited, 3013 Lake Drive, Citywest Business Campus, Dublin 24, D24PPT3, Ireland
PL 52637/0008
23 October 1995 / 23 October 2005
| Drug | Countries | |
|---|---|---|
| XENAZINE | Estonia, France, Israel, Lithuania, Netherlands, United Kingdom, United States |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
